Abstract : A 27 -year -old woman exhibited progressive pancytopenia during cyclophosphamide pulse therapy for lupus nephritis and low -dose methotrexate therapy for severe arthralgia. Bone marrow aspiration revealed highly abnormal cell morphology, indicating therapy -related myelodysplastic syndrome. Pancytopenia and bone marrow cell morphology improved 3 months after discontinuation of cyclophosphamide. It is necessary to promptly examine bone marrow cell morphology and chromosomal aberration in cases with connective tissue diseases complicated by sudden cytopenia during immunosuppressive therapy with chemotherapeutic agents.
INTRODUCTION
Two types of myelodysplastic syndrome (MDS) are known : primary MDS of unknown cause ; and therapy -related MDS (T -MDS) that follows administration of antitumor drugs or radiation. T -MDS frequently develops in patients with hematopoietic neoplasms who have received large amounts of antitumor drugs 1, 2) , although T -MDS has also been reported in cases with connective tissue diseases 2−4) . T -MDS is generally resistant to therapy and has poor prognosis 1, 2) . It is often accompanied by chromosomal aberrations 1, 2) , and few cases achieve spontaneous remission. Here, we report a rare case of systemic lupus erythematosus that transiently revealed bone marrow cell morphology compatible with MDS during immunosuppressive therapy with cyclophosphamide (CYC) and/or methotrexate (MTX).
CASE REPORT
In 1991, a 16 -year old woman exhibited high fever, butterfly rash and photosensitivity, and was diagnosed with systemic lupus erythematosus (SLE) at a local clinic. She was treated with prednisolone (PSL), but continued to have relapses and was referred to our department in 1997 (at age 22 years).
In September 1997, renal biopsy was performed as her urine protein became positive, and she was diagnosed with lupus nephritis (WHO IIIB). She received methyl -PSL pulse therapy followed by CYC pulse therapy (total dose, 3,400 mg) but proteinuria continued. In addition, methotrexate (MTX) at 4 mg/week (total dose, 768 mg) was administered due to high fever and arthralgia, and the amount of PSL was then decreased gradually.
Proteinuria again developed in February 2002. In June, a second renal biopsy was performed, and she was diagnosed with lupus nephritis (WHO IVC). After receiving CYC pulse therapy for 3 months (monthly dose, 750 mg/month ; total dose, 2,250 mg), proteinuria decreased. However, from the end of August, a high fever of 39°C or more appeared once per week, and anemia progressed simultaneously. The patient was admitted to our department in September 2002 (at age 27 years).
On admission, her palpebral conjunctiva was anemic, and subcutaneous hematoma was observed in the right lower leg. Superficial lymph nodes were not palpable. Laboratory tests revealed an increased erythrocyte sedimentation rate of 41 mm in 1 hour, and a white blood cell count of 9,400/μl (11% Band ; 64% Seg ; 5% Ly ; 11% Mo ; 5% Eo ; 2% Myelo ; 1% Meta), decreased hemoglobin of 6.0 g/dl, and platelet count of 11 5) . Slightly hypercellularity of bone marrow was noted in the biopsied sample, but no chromosomal aberrations were present. T -MDS was suspected because bone marrow cell morphology was highly abnormal and had developed during CYC pulse and low -dose 1, 2) , and the other half have various cancers, although there have also been reports of cases with nonneoplastic disorders, including collagen diseases such as SLE, Behçet's syndrome, and rheumatoid arthritis (RA) 2−4,6−13) (Table 2) .
Drugs for chemotherapy, particularly alkylating agents such as melpharan and CYC are more likely to induce T -MDS 14, 15) . Alkylating agents are known to decrease hematopoetic potential for pluripotent stem cells and cause bone marrow hypoplasia. It has been suggested that T -MDS develops based on hematopoietic stem cells injured by chemotherapeutic agents during convalescesce from 2) , and the condition is often resistant to therapy 1, 2) . WHO classifications are difficult to apply to T . The relative risk of T -MDS and T -AML development by cytostatic agents is 100 times or more that of primary diseases 16) ; this is presumed to be dependent on total dose 17) . Total dose of CYC in this case was 5,650 mg, which did not reach the 20,000 mg considered to influence the relative risk of CYC. Furthermore, bone marrow cell morphology improved 3 months after discontinuation of CYC, and no chromosomal aberrations were seen. For these reasons, a diagnosis of typical T -MDS was not confirmed.
Michels et al. suggested that there are three stages of therapy -related panmyelosis : (1) pancytopenia associated with myelodysplastic changes in which the marrow blast count is frequently <5% ; (2) frank MDS ; and (3) overt AML 2) . It is possible that this case was in the early stages of T -MDS/ T -AML, although long -lasting spontaneous improvement is extremely rare in MDS patients 18) . The patient had been receiving MTX at a dose of 4 mg/week for the treatment of severe arthritis. MTX suppresses DNA sysnthesis by inhibiting dihydrofolate reductase, and its chromosome -breaking effect leads to damage in bone marrow cells 19) . There have been several reports and case series in which hematological malignancies have developed in autoimmune diseases receiving MTX 4,20−25) . In particular, there have been case reports of lymphomas and lymphoproliferative disorders (LPDs), developing during MTX therapy for autoimmune diseases, and spontaneously regressing shortly after discontinuation of treatment. Such LPDs are considered to be MTX -associated LPDs, and are recognized by the WHO among the immunodeficiency -associated LPDs 26) . Although rarely described, MDS have been reported patients with autoimmune diseases after MTX therapy 27−29) . Moreover, a relationship between the use of MTX and T -MDS has not been demonstrated 30−33) . However, it is possible that combined therapy with MTX and CYC influenced the development of T -MDS in this case. There have only been two case reports on complicating SLE and MDS 34, 35) , and in those cases, MDS developed before SLE, and one showed chromosomal aberrations 35) . In this case, it was difficult to infer whether MDS was related to SLE.
Some viruses, including HIV, are known to induce hematopoietic failure, such as in MDS. It has been reported that parvovirus B 19 infection elicits transient MDS -like bone marrow findings 36, 37) , and these cases resulted in spontaneous improvement without treatment. In this case, there was no evidence of viral infection by HIV, parvovirus, cytomegalovirus or EB virus. However, an unknown infection cannot be excluded as a cause of hematopoietic failure, as the patient had high fever before the occurrence of pancytopenia.
Consequently, it is noteworthy that the hematopoietic failure in this case was in the early stages of T -MDS induced by CYC and/or MTX. Alkylating agents are frequently administrated to patients with connective tissue diseases, and cytopenia is one of the most common side effects of the drug. It is thus necessary to promptly examine bone marrow cell morphology and chromosomal aberrations in cases with sudden cytopenia during immunosuppressive therapy with chemotherapeutic agents.
